DMCC Speciality Chemicals Ltd

Q1 FY20 Earnings Call Analysis

Chemicals & Petrochemicals

Full Stock Analysis
fundraise: Yescapex: Yesrevenue: Category 4margin: Category 3orderbook: No information
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Expansion completions expected by first half of 2021, enabling further capacity utilization and growth. - Sulfuric acid and sulfone plants are undergoing validation; contracts awaited before further investment, signaling cautious growth. - Debottlenecking efforts at Roha plant aim to increase output without major investments. - Multipurpose plants at Dahej are operational but not at full capacity, suggesting room for ramp-up. - Specialty products and new boron products are being explored to offset stagnation in borax business. - Competition from China intensifies, with China providing subsidies to their manufacturers; domestic growth faces challenges. - Gross margins improved recently due to raw material cost reductions and higher specialty product mix. - Management cautious on leverage and capital expenditures until contracts are secured, implying measured profit growth. - Earnings growth expected post validation and contract wins, targeting improved operational profits and EPS in coming quarters.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- The company is currently facing some delay in new orders, especially on the boron side, partly due to regulatory delays such as the boric acid registration with BIS which was lost for about 4-5 months. - Validation for sulfone products is complete, but actual business pickup is slower than expected due to market turmoil and reduced demand. - Contracts from clients, especially for sulfone and specialty products, are pending; management is waiting for client contracts to proceed further. - The company has made investments of around ₹50 crores in multipurpose plants with flexible production options, expected to be fully utilized within the next 1 to 1.5 years. - Competition from China is aggressive due to export subsidies, impacting market share and contract inflow. - Because of uncertainties, management prefers to defer further leverage until contracts are secured.
💰

fundraise

Any current/future new fundraising through debt or equity?

- The company currently has about ₹50 crore investments in sulfuric acid, oleum, and chlorosulfonic acid plants, and another ₹20 crore for one of the plants. - They do not want to be very aggressive with borrowings under the current conditions. - Further expansion and investments will depend on securing firm contracts. - If certain of contracts, they will proceed with further debt or equity fundraising; otherwise, they will defer. - No explicit mention of immediate new fundraising through equity or debt, but future fundraising is contingent on confirmed contracts and market conditions.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- The company plans a shutdown in Q3 (typically 3 weeks to 1 month) for repairs and debottlenecking without major investment as of now, with more extensive shutdown in Oct-Dec quarter. - Around ₹50 crore investment is committed in sulfuric acid and oleum and chlorosulfonic acid plants. - Approximately ₹20 crore invested in multipurpose plants, with ongoing production but not yet at full capacity. - Debottlenecking investments are being made at Roha plant to increase output without major capital expenditure. - Further expansion is planned dependent on client contracts and market conditions, especially for sulfuric acid and sulfone products. - The company is cautious about aggressive borrowing and will proceed with new investments only when contracts are certain (clarity expected by August-September). - Expansion completion timelines have shifted to the first half of 2021 from 2020 due to delays.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- Expansion completion expected in first half of 2021, focusing on Roh plant debottlenecking and multipurpose plants at Dahej, which should increase output without major investments. - Flexible multipurpose plants allow quick switching between products based on client contracts, aiding revenue growth. - Specialty products show promise, with increased volumes expected to be fully utilized within 1.5 years. - Raw material prices have decreased compared to previous years, which previously allowed volume increase despite lower top-line; future margins may improve with stabilization. - Export market had a low in Q3 FY20 due to COVID-19 but picked up in January, indicating recovery and growth potential. - Competitive pressures from China (e.g., 13% export subsidy) will impact business but also drive market activity. - Company cautious on further borrowing, awaits firm contracts before additional investments.